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The benefits of endurance exercise on general health
make it desirable to identify orally active agents that
would mimic or potentiate the effects of exercise to
treat metabolic diseases. Although certain natural
compounds, such as reseveratrol, have endurance-
enhancing activities, their exactmetabolic targets re-
main elusive. We therefore tested the effect of path-
way-specific drugs on endurance capacities of mice
in a treadmill running test. We found that PPARb/
d agonist and exercise training synergistically in-
crease oxidative myofibers and running endurance
in adult mice. Because training activates AMPK and
PGC1a, we then tested whether the orally active
AMPK agonist AICAR might be sufficient to over-
come the exercise requirement. Unexpectedly,
even in sedentary mice, 4 weeks of AICAR treatment
alone induced metabolic genes and enhanced run-
ning endurance by 44%. These results demonstrate
that AMPK-PPARd pathway can be targeted by orally
active drugs to enhance training adaptation or even
to increase endurance without exercise.
INTRODUCTION
Skeletal muscle is an adaptive tissue composed of multiple my-
ofibers that differ in their metabolic and contractile properties,
including oxidative slow-twitch (type I), mixed oxidative-glyco-
lytic fast-twitch (type IIa) and glycolytic fast-twitch (type IIb) my-
ofibers (Pette and Staron, 2000; Fluck andHoppeler, 2003). Type
I fibers preferentially express enzymes that oxidize fatty acids,
contain slow isoforms of contractile proteins, and are more
resistant to fatigue than are glycolytic fibers. Type II fibers pref-
erentially metabolize glucose and express the fast isoforms of
contractile proteins. Endurance exercise training triggers a re-
modeling program in skeletal muscle that progressivelyenhances performance in athletes such as marathon runners,
mountain climbers, and cyclists. This involves change in meta-
bolic programs and structural proteins within the myofiber that
alter the energy substrate utilization and contractile properties
that act to reduce muscle fatigue (Pette and Staron, 2000; Fluck
and Hoppeler, 2003). Training-based adaptations in the muscle
are linked to increases in the expression of genes involved in
the slow-twitch contractile apparatus, mitochondrial respiration,
and fatty acid oxidation (Holloszy and Coyle, 1984; Booth and
Thomason, 1991; Schmitt et al., 2003; Yoshioka et al., 2003; Ma-
honey et al., 2005; Mahoney and Tarnopolsky, 2005; Siu et al.,
2004; Garnier et al., 2005; Short et al., 2005; Timmons et al.,
2005). These adaptations that improve performance can also
protect against obesity and related metabolic disorders (Wang
et al., 2004; Koves et al., 2005). Moreover, skeletal muscles
rich in oxidative slow-twitch fibers are resistant to muscle wast-
ing (Minnaard et al., 2005).
Given the numerous benefits of exercise on general health,
identification of orally active agents that mimic or potentiate
the genetic effects of endurance exercise is a long-standing, al-
beit elusive, medical goal. High doses of certain natural extracts
such as resveratrol can improve endurance (Lagouge et al.,
2006). The aerobic effects of resveratrol are thought to depen-
dent on activation of SIRT1-PGC1a coactivator complex in skel-
etal muscle. However, the downstream transcriptional factor(s)
targeted by SIRT1/PGC1a in mediating these effects are not
known. More importantly, both SIRT1/PGC1a and resveratrol
activate multiple targets, and thus whether there is a specific
signaling pathway that can be selectively activated by a synthetic
drug to improve endurance is not known.
Exercise training activates a number of transcriptional regula-
tors and serine-threonine kinases in skeletal muscles that con-
tribute to metabolic reprogramming (Bassel-Duby and Olson,
2006). We and others previously identified a critical role for
PPARb/d (henceforth referred to as PPARd) in transcriptional
regulation of skeletal muscle metabolism (Dressel et al., 2003;
Luquet et al., 2003; Schuler et al., 2006; Wang et al., 2004).
Overexpression of a constitutively active PPARd (VP16-PPARd)
in skeletal muscles of transgenic mice preprograms an increaseCell 134, 405–415, August 8, 2008 ª2008 Elsevier Inc. 405
in oxidative muscle fibers, enhancing running endurance by
nearly 100% in untrained adult mice (Wang et al., 2004). One
of the best understood serine-threonine kinases is AMP-acti-
vated protein kinase (AMPK), a master regulator of cellular
and organismal metabolism whose function is conserved in
all eukaryotes (Hardie, 2007). In mammals, AMPK has been
shown to contribute to glucose homeostasis, appetite, and ex-
ercise physiology (Andersson et al., 2004; Hardie, 2007; Kubota
et al., 2007; Mu et al., 2001; Minokoshi et al., 2004; Thomson
et al., 2007). These observations raise the question as to
whether synthetic PPARd or AMPK agonists can reprogram
established fiber specification in adult muscle toward an overt
endurance phenotype. We have found that the PPARd agonist
GW1516 (shown to be bioactive in humans; Sprecher et al.
[2007]) enables mice to run 60%–75% longer and further than
the nontreated controls only when combined with exercise
training. This ‘‘super-endurance phenotype’’ is linked to a tran-
scriptional boost provided by exercise-activated AMPK
resulting in a novel endurance gene signature. A more critical
role of AMPK in the super-endurance phenotype is revealed
in our unexpected finding that the orally active AMPK agonist
AICAR is sufficient as a single agent to improve running endur-
ance by nearly 45% in nonexercised mice. Together, these re-
sults provide new insights into the pharmacological malleability
of muscle performance.
RESULTS
GW1516 Increases Muscle Gene Expression
but Not Endurance in Sedentary Mice
To examine whether treatment with PPARd ligands alone can
reprogram the muscle transcriptome and endurance capacity,
we treated wild-type C57Bl/6J age matched cohorts with
vehicle or GW1516 for 4 weeks. QPCR analysis of selective tar-
get genes confirmed that drug treatment induced oxidative
metabolic biomarkers such as uncoupling protein 3 (Ucp3),
muscle carnitine palmitoyl transferase I (mCPT I, Cpt 1b), and
pyruvate dehydrogenase kinase 4 (Pdk4) (Figure 1A). These
changes in gene expression were detected as early as 4 days
after treatment, as well as with drug concentrations ranging
from 2–5 mg/kg/day. Moreover, in all our gene expression stud-
ies, maximal effects of PPARd activation were detected in pre-
dominantly fast-twitch (quadricep and gastrocnemius) but not
slow-twitch (soleus) muscles (data not shown). In primary mus-
cle cells cultured from wild-type and PPARd null mice (Chawla
et al., 2003; Man et al., 2007), we confirmed that the induction
of oxidative genes by GW1516 is mediated via selective activa-
tion of PPARd in skeletal muscles (Figures S1A–S1C available
online). Moreover, this is similar to the expression changes
found in the same genes in muscles expressing the constitu-
tively active VP16-PPARd transgene (Wang et al., 2004)
(Figure 1A), supporting the concept that pharmacological acti-
vation of PPARd is sufficient to initiate an oxidative response in
adult skeletal muscle. To determine the functional effects of li-
gand, age- and weight-matched cohorts of treated and control
mice were subjected to an endurance treadmill performance
test before (week 0) and after (week 5) treatment. Curiously,
running performance was unchanged by GW1516 treatment406 Cell 134, 405–415, August 8, 2008 ª2008 Elsevier Inc.(Figure 1B). Furthermore, long-term drug treatment of up to 5
months also did not change running endurance (data not
shown). These results indicate that pharmacologic activation
of the PPARd genetic program in adult C57Bl/6J mice is
insufficient to promote a measurable enhancement of treadmill
endurance.
Figure 1. Synthetic PPARd Activation in Mice
(A) Relative gene expression levels of Ucp3, Cpt1b, and Pdk4 in quadriceps
isolated from vehicle (V)- and GW1516 (GW)-treated wild-type mice, as well
as frommuscle VP16-PPARd transgenic (Wang et al., 2004) (TG) and nontrans-
genic (WT) littermates. Data are presented asmean ±SEM (n = 4–9). * indicates
statistically significant differences between GW and V groups or TG and WT
groups (p < 0.05, unpaired student’s t test).
(B) Running endurance in sedentary mice. Endurance was tested in V- (open
bars) and GW- (black bars) treated wild-type mice before (Week 0) and after
(Week 5) treatment. Data are represented as mean ± SD (n = 6).
(C) Representative metachromatically stained frozen gastrocnemius cross-
sections from vehicle-treated sedentary (V), GW1516-treated sedentary
(GW), vehicle-treated exercised (Tr), and GW-treated exercised (Tr+GW)
mice. Type I fibers are stained dark blue.
(D) Type I fiber quantification (n = 3).
(E) Fold change in mitochondrial DNA to nuclear DNA ratio (n = 9).
Data in (D) and (E) are presented as mean ± SEM. * indicates statistical differ-
ences between V and indicated groups (p < 0.05, one-way ANOVA; post hoc:
Dunnett’s multiple comparison test).
GW1516 Remodels Skeletal Muscle
in Exercise-Trained Mice
Since endurance exercise remodels the skeletal muscle to pro-
gressively alter performance (Holloszy and Coyle, 1984; Booth
and Thomason, 1991; Schmitt et al., 2003; Yoshioka et al.,
2003; Mahoney et al., 2005; Mahoney and Tarnopolsky, 2005;
Siu et al., 2004; Garnier et al., 2005; Short et al., 2005; Timmons
et al., 2005), we speculated whether coadministration of
GW1516 in the context of exercise training might enhance an-
ticipated changes in fiber type composition and mitochondrial
biogenesis. The effect of GW1516 and exercise on fiber type
composition was determined via metachromatic staining of
cryosections of the gastrocnemius (Wang et al., 2004). As ex-
pected from the results of the running performance in
Figure 1B, there was no significant difference in the proportion
of type I fibers between vehicle- and GW1516-treated sedentary
mice (Figure 1C). In contrast, in trained mice, GW1516 increased
the proportion of type I fibers (by 38%) compared to the vehi-
cle-treated sedentary mice (Figures 1C and 1D). In addition to its
effects on the fiber type, exercise training increases skeletal
muscle mitochondrial biogenesis, which was measured as
a function of mitochondrial DNA expression levels via quantita-
tive real-time PCR (QPCR). Similar to type I fiber changes, mito-
chondrial DNA expression was not changed by drug alone but
was increased by approximately 50% with the combination of
exercise and GW1516 treatment (Figure 1E).
The effects of GW1516 treatment and exercise, singly or in
combination, on components of the oxidative metabolism of
fatty acids were further analyzed by measurement of the gene
expression levels of selective biomarkers for fatty acid b oxida-
tion. As expected, we found that previously examined genes
such as Ucp3, Cpt 1b, and Pdk4 were upregulated by GW1516
but showed no further induction with exercise (Figure 2A). Unex-
Figure 2. Gene and Protein Expression in
Quadriceps
(A–C) Relative gene expression levels of FAO
(Ucp3, Cpt 1b, Pdk4) (A), fatty acid storage
(Scd1, Fasn, Srebf1c) (B), and fatty acid uptake
(Cd36, Lpl) (C) biomarkers in quadriceps from V,
GW, Tr, and Tr+GW groups. Data are presented
as mean ± SEM (n = 9). * indicates statistically
significant difference between V and indicated
groups (p < 0.05, one-way ANOVA; post hoc: Dun-
nett’s multiple comparison test).
(D) Protein expression levels of oxidative bio-
markers (myoglobin, UCP3, CYCS, SCD1) and
loading control (tubulin) in quadriceps (n = 3).
pectedly, we discovered a second set of
genes that show no response to exercise
or drug alone but are robustly induced by
the combination. This intriguing response
profile includes a series of genes involved
in the regulation of fatty acid storage
(such as steroyl-CoA-desaturase [Scd1],
fatty acyl coenzyme A synthase [FAS,
Fasn] and serum response element bind-
ing protein 1c [SREBP1c, Srebf1c]) and
fatty acid uptake (such as the fatty acid transporter [FAT,
Cd36] and lipoprotein lipase [Lpl]) (Figures 2B, 2C, and 3).
We also measured the protein levels of selective oxidative bio-
markers including myoglobin, UCP3, cytochrome c (CYCS), and
SCD1. In each case, a more robust upregulation of protein ex-
pression was found by combining exercise and GW1516 treat-
ment relative to either drug or exercise alone (Figure 2D). Altered
triglycerides are one way to assess changes in muscle oxidative
capacity. Triglyceride levels were unchanged in vehicle- or
GW1516-treated sedentary mice but showed a striking increase
with exercise. In contrast, this increase was completely reversed
by GW1516 treatment, presumably because of enhanced fat
utilization (Figure S1D).
GW1516 and Exercise Training Synergistically
Increase Running Endurance
As described above, although GW1516 treatment alone induces
widespread genomic changes associated with oxidative metab-
olism, it fails to increase running endurance. On the other hand,
drug treatment in conjunction with exercise produces an
enriched remodeling program that includes a series of transcrip-
tional and posttranslational adaptations in the skeletal muscle.
This suggests that exercise training serves as a key trigger to
unmask a cryptic set of PPARd target genes, leading us to re-ex-
amine the ability of the drug to modulate endurance. Indeed, the
same dose and duration of GW1516 treatment that previously
failed to alter performance, when paired with 4 weeks of exercise
training, increases running time by 68% and running distance
by 70% over vehicle-treated trained mice (Figures 3A and 3B,
compare week 5). It is also important to note that comparison
of running time and distance before (week 0) and after (week 5)
exercise and drug treatment revealed a 100% increment in
endurance capacity for individual mice, underscoring theCell 134, 405–415, August 8, 2008 ª2008 Elsevier Inc. 407
robustness of the combination paradigm (Figures 3A and 3B). Fi-
nally, it is noteworthy that the combined effects of GW1516 and
exercise reduces the ratio of epididymal fat to body weight and
fat cross-sectional area in these mice (Figures S1E and S1F),
suggesting the broader systemic effects of this protocol.
PPARd Agonist and Exercise Establish
an Endurance Gene Signature
To dissect the mechanism underlying the super-endurance phe-
notype, we conducted a comprehensive study of the muscle
transcriptome induced by ligand, exercise, or the combination,
which produced three overlapping networks of 96, 113, and
130 genes, respectively (Figure 3C). Approximately 50% of the
target genes were common between GW1516 and exercise,
demonstrating that PPARd activation partially mimics exercise.
To our surprise, combined GW1516 treatment and exercise es-
tablished a unique gene expression pattern that was neither an
amalgamation nor a complete overlap of the individual interven-
tions (Figure 3C). This signature included 48 new target genes
(Table S1) not regulated by either GW1516 or exercise alone
Figure 3. Running Endurance andGeneSig-
nature in Exercise-Trained Mice
(A and B) Running endurance was tested in V-
(open bars) and GW- (black bars) treated mice be-
fore (Week 0) and after (Week 5) exercise training.
Running endurance is depicted as time (A) and
distance (B) that animals in each group ran. Data
are represented as mean ± SD (n = 6). *** indicates
statistically significant difference between V- and
GW-treated exercised mice (p < 0.001) (one-way
ANOVA; post hoc: Tukey’s multiple comparison
test).
(C) Venn diagram comparing GW, Tr, and Tr+GW
target genes identified in microarray analysis of
quadriceps (n = 3). The selection criteria used
a p < 0.05 on Bonferroni’s multiple comparison
test.
(D) Classification of target genes in Tr+GW mice.
(E) Relative expression of 48 unique TR+GW target
genes in GW, TR, TR+GW, and VP16-PPARdmus-
cles. Each condition is represented by data from
two samples (each sample is pooled from three
mice). (Color scheme for fold change is provided.)
while excluding 74 genes regulated by
GW1516 or exercise (selective genes
are listed in Table S3). The majority of
the genes in the GW1516-exercise signa-
ture were induced (108/130), the com-
ponents of which are described in
Figure 3D. Although the largest gene sub-
class (32% of genes) was linked to
positive regulation of aerobic capacity,
additional pathways implicated in muscle
remodeling and endurance were also
represented in the signature (see Table
S2 for detailed description). It is notewor-
thy that comparative expression analysis
of the 48 exclusive genes of the endurance signature (but not
of either intervention alone) revealed a striking similarity to
‘‘untrained’’ VP16-PPARd transgenic mice (Figure 3E). This
observation confirms the primary dependence of the 48
genes on PPARd and points to the possibility that exercise-
generated signals may function to synergize PPARd transcrip-
tional activity to levels comparable to transgenic overexpression.
AMPK-PPARd Interaction in Transcriptional Regulation
What might be the molecular interface between mechanical
exercise and PPARd transcription? Exercise training is known
to activate multiple kinases, among which AMPK has profound
effects on skeletal muscle gene expression and oxidative
metabolism (Chen et al., 2003; Reznick and Shulman, 2006).
Indeed, mice defective for AMPK signaling in muscle exhibit
reduced capacity for voluntary running (Mu et al., 2001;
Thomson et al., 2007). As previously observed (Durante
et al., 2002; Frøsig et al., 2004), we found increased AMPK ac-
tivation in the quadriceps of exercised mice relative to the sed-
entary controls (Figure 4A). Furthermore and unexpectedly,
AMPK is constitutively activated in muscles of VP16-PPARd408 Cell 134, 405–415, August 8, 2008 ª2008 Elsevier Inc.
transgenic mice in absence of exercise or drug (Figure 4B). In
contrast, in our experiments, GW1516 treatment alone does
not activate AMPK in either sedentary or exercise trained mus-
cles, as previously suggested by some (Terada et al., 2006)
but not by others (Kramer et al., 2005, 2007). Taken together,
these results strongly suggest that the ability to promote en-
durance in mice is associated with activation of both AMPK
and PPARd.
According to this hypothesis, selective coactivation of AMPK
and PPARd would induce gene expression changes that mimic
those triggered by combined exercise and PPARd as well as
VP16-PPARd overexpression. To investigate this possibility,
we compared the transcriptional changes induced in skeletal
muscle by combined exercise and GW1516 treatment with
that of combined AMPK activator (the cell-permeable AMP an-
alog AICAR) and GW1516 treatment. It is noteworthy that si-
multaneous GW1516 and AICAR treatment created a unique
gene expression signature in the quadriceps of untrained
C57Bl/6J mice (Figure S2) that shares 40% of the genes with
Figure 4. Synergistic Regulation of Muscle
Gene Expression by PPARd and AMPK
(A and B) AMPK activation by exercise (A) and
VP16-PPARdoverexpression (B) in skeletalmuscle.
(C) Comparison of Tr+GW and AI+GW dependent
gene signatures in quadriceps (N = 3). The selec-
tion criteria used is similar to one used in
Figure 3C.
(D) Classification of 52 targets that were common
to Tr+GW and AI+GW gene signatures.
(E–J) Expression of Scd1 (E), ATP citrate lyase
(Acly) (F), HSL (Lipe) (G), Fabp3 (H), Lpl (I), and
Pdk4 (J) transcripts in quadriceps of mice treated
with vehicle (V), GW1516 (GW, 5 mg/kg/day),
AICAR (AI, 250 mg/kg/day), and the combination
of the two drugs (GW+AI) for 6 days. Data are pre-
sented as mean ± SEM (n = 6). * indicates statisti-
cally significant difference between V and indi-
cated groups (p < 0.05, one-way ANOVA; post
hoc: Dunnett’s multiple comparison test).
that of combined GW1516 treatment
and exercise (Figure 4C). Classification
of the 52 genes common to the two sig-
natures (Figure 4D, listed in Table S4) re-
vealed that the majority of the targets
were linked to oxidative metabolism.
Quantitative expression analysis of se-
lective oxidative genes by QPCR
showed that several of these bio-
markers, including Scd1, ATP citrate ly-
ase (Acly), hormone sensitive lipase
(HSL) (Lipe), muscle fatty acid binding
protein (mFABP, Fabp3), Lpl, and Pdk4,
were induced in a synergistic fashion
by GW1516 and AICAR in the quadri-
ceps (Figures 4E–4J). It is also notewor-
thy that all of the above genes were
induced in quadriceps of untrained
VP16-PPARd mice, where AMPK is constitutively active
(Figure S1G). Collectively, these results show that interaction
between AMPK and PPARd substantially contributes to
reprogramming of the skeletal muscle transcriptome during
exercise.
AMPK Increases Transcriptional Activation by PPARd
The above described pathway crosstalk raised the possibility
that AMPK directly regulates the transcriptional activity of
PPARd in skeletal muscles. An analysis of the effects of
GW1516 and AICAR on gene expression in primary muscle cells
isolated from wild-type and PPARd null mice revealed that syn-
ergism is completely dependent on PPARd and lost in the null
cells (Figures 5A–5D). These observations show that AMPK
enhances a subset of ligand-dependent PPARd transcriptional
targets in a cell-autonomous fashion.
To more directly examine this connection, we utilized re-
porter gene expression assays. Cotransfection of either cata-
lytic AMPK a1 or a2 subunits but not control vector withCell 134, 405–415, August 8, 2008 ª2008 Elsevier Inc. 409
PPARd increased the basal (Figure 5E) and GW1516-depen-
dent transcriptional activity (Figure 5F) of PPARd in inducing
a PPRE-driven reporter gene in AD293 cells. It should be noted
that AMPK overexpression or GW1516 treatment did not
change reporter activity in transfections excluding the PPARd
expression vector (data not shown), negating the possibility
of an effect via RXR. Additionally, in AD293 cells cotransfected
with Flag-PPARd and with either catalytic AMPK a1 or a2 sub-
units, we discovered that each of the AMPK subunits coimmu-
noprecipitated as a complex with Flag-PPARd (Figure 5G).
Furthermore, Flag-PPARd coimmunoprecipitated endogenous
AMPKa subunits from AD293 cells, confirming a tight physical
interaction between the nuclear receptor and the kinase
(Figure 5H). Despite this association, AMPK failed to increase
PPARd phosphorylation. In vivo orthophosphate labeling of
PPARd in AD 293 cells in the presence or absence of either
AMPK alpha isoform under the same conditions where AMPK
promotes PPARd-dependent transcription revealed no change
in overall PPARd phosphorylation (Figure 5I). These data sug-
gest that PPARd phosphorylation is not increased by AMPK
in vivo. However, cotransfection of AMPKa2 and coactivator
PGC1a (a previously reported direct substrate of AMPK) coop-
eratively interact to further induce both the basal and ligand-
Figure 5. AMPK-PPARd Interaction
(A–D) Expression of metabolic genes in wild-type and PPARd
null primary muscle cells treated with V, GW, AI, and GW+AI
for 24 hr.
(E–F and J) AD293 cells were transfected with PPARd+RX-
Ra+Tk-PPRE along with control vector, AMPK a1, a2, and/
or PGC1a as indicated.
(E) Induction of basal PPARd transcriptional activity by AMPK
a1 or a2.
(F) Dose-dependent induction of PPARd transcriptional activ-
ity is enhanced by AMPKa1 (closed circle) or AMPK a2 (closed
square) compared to control (open triangle).
(G–I and K) AD293 cells were transfected and processed as
indicated.
(G–H) Representative blot showing coimmunoprecipitation of
transfected (G) or endogenous (H) AMPK with Flag-PPARd.
(I) Metabolic p32 labeling of PPARd in AD293 cells transfected
as described.
(J) Synergistic regulation of basal (V) and ligand (GW) depen-
dent PPARd transcriptional activity by AMPK a2 subunit and
PGC1a.
(K) Coimmunoprecipitation of PPARd but not AMPK a2 sub-
unit with Flag-PGC1a.
Data in (A)–(D) (n = 6), (E), and (J) (n = 3–4) are presented as
mean ± SEM, and * indicates statistical significance (p < 0.05,
one-wayANOVA;posthoc:Dunnett’smultiplecomparisontest).
dependent transcriptional activity of PPARd
(Figure 5J). Strikingly, we did not detect physical
interaction between Flag-PGC1a and AMPK
(Figure 5K), though both independently interacted
with PPARd. Collectively, these observations
suggest that AMPK may be present in a transcrip-
tional complex with PPARd, where it can potenti-
ate receptor activity via direct protein-protein
interaction and/or by phosphorylating coactivators such as
PGC1a.
Pharmacologic AMPK Activation Increases
Running Endurance in Untrained Mice
Our findings show that pharmacologic activation of PPARd in
adult mice can increase running endurance only in conjunction
with exercise signals. The central role for AMPK in this process
is especially underscored by the observations that it is both ro-
bustly stimulated by exercise as well as constitutively active in
muscles of VP16-PPARd transgenic mice that exhibit endurance
without exercise. Further, AMPK can integrate multiple tran-
scriptional programs by interacting not only with PPARd but
also other transcriptional regulators of metabolism (e.g.,
PGC1a, PPARa) (Hong et al., 2003; Leff, 2003; Bronner et al.,
2004; Ja¨ger et al., 2007). This raises the interesting question as
to whether chemical activation of AMPK is sufficient to increase
running endurance without exercise.
To test this idea we treated C57B/6J mice with AICAR (500
mg/kg/day) for 4 weeks. AICAR increased phosphorylation of
AMPK a subunit and acetyl CoA carboxylase (ACC) and in-
creased expression of UCP3 in quadriceps, confirming effective
activation of AMPK signaling (Figure 6A). Interestingly, 4 weeks410 Cell 134, 405–415, August 8, 2008 ª2008 Elsevier Inc.
of drug treatment decreased the ratio of epididymal fat mass to
body weight and increased oxygen consumption without chang-
ing body weight (Figures 6B–6E), supporting the speculation that
AICAR may positively regulate endurance. Indeed, in a tread-
mill endurance test, ACIAR-treated mice ran longer (23%) and
further (44%) than did vehicle-treated mice, revealing that
increase in endurance can be achieved without exercise
(Figure 6F). Furthermore, global gene expression analysis of
quadriceps revealed that AICAR treatment alone upregulated
a set of 32 genes linked to oxidative metabolism (Figure 6G
and Table S5). Notably, 30 of these 32 genes were also upregu-
lated in VP16-PPARd transgenic mice, suggesting that stimula-
tion of oxidative genes by AMPK may depend on PPARd (Table
S5). To test this possibility, we utilized wild-type and PPARd null
primary muscle cells. Treatment of wild-type primary cells with
Figure 6. AICAR Increases Running Endur-
ance
(A–F) C57Bl/6J mice were treated with vehicle
(open bars or thin lines) or AICAR (500 mg/kg/
day, 4 weeks) (closed bars or thick lines).
(A) Representative immunoblots showing levels of
UCP3, phospho-acetyl CoA carboxylase (ACC),
phospho-AMPK, and total-AMPK in quadriceps.
(B) Average body weight.
(C) Percent epididymal fat mass to body weight
ratio.
(D) Oxygen consumption rates (mg/kg/hr) mea-
sured over 12 hr period.
(E) Data in (D) represented as AUC.
(F) Running endurance measured as a function of
time (upper panel) and distance (lower panel).
(G) Representative oxidative genes induced by
AICAR treatment (250 mg/kg/day, 6 days).
(H) Expression of oxidative biomarkers (Scd1,
Fasn, Ppargc1a, Pdk4) in wild-type and PPARd
null primary myoblast treated with vehicle (open
bars) or AICAR (closed bars) for 72 hr.
(I) Model depicting the interaction between exer-
cise and AMPK-PPARd in reprogramming muscle
genome.
Data in (B) and (C) (n = 10), (D) and (E) (n = 4), (F) (n =
15–20), and (H) (n = 9) are presented as mean ±
SEM, and * indicates statistical significance (p <
0.05, unpaired student’s t test).
AICAR (for 72 hr) increased expression
of key oxidative biomarker genes (Scd1,
fasn [FAS], Ppargc 1a, Pdk4) (Figure 6H).
In contrast, AICAR failed to increase the
expression of the above genes in PPARd
null cells, demonstrating the requirement
of the receptor for transcriptional effects
of AMPK on oxidative genes.
DISCUSSION
In this study, we show that the AMP-mi-
metic AICAR can increase endurance
in sedentary mice by genetically re-
programming muscle metabolism in
a PPARd-dependent manner. We also found that a PPARd ago-
nist in combination with exercise synergistically induces fatigue-
resistant type I fiber specification and mitochondrial biogenesis,
ultimately enhancing physical performance. These changes cor-
relatewith an unexpectedbut interesting establishment of amus-
cle endurance gene signature that is unique to the drug-exercise
paradigm. Such a signature is an outcome ofmolecular crosstalk
and perhaps a physical association between exercise-activated
AMPK and PPARd. These findings identify a novel pharmaco-
logic strategy to reprogram muscle endurance by targeting
AMPK-PPARd signaling axis with orally active ligands.
Transgenic overexpression as well as knockout studies have
identified PPARd and AMPK as key regulators of type I fiber
specification and endurance adaptations during exercise (Mu
et al., 2001; Ro¨ckl et al., 2007; Thomson et al., 2007; WangCell 134, 405–415, August 8, 2008 ª2008 Elsevier Inc. 411
et al., 2004). Whether and how these endogenously expressed
regulators can be targeted to reprogram adult muscle without
exercise has been a subject of unresolved speculation.We found
that the AMPK activator AICAR increased oxygen consumption
and endurance in untrained adult mice in part by stimulating
PPARd-dependent oxidative genes. Despite a demonstrated
role for PPARd in endurance, 4 week treatment with a potent
and selective agonist failed to alter either fiber type composition
or endurance, revealing that direct and pharmacologic activation
of PPARd is insufficient to enhance running performance. In con-
trast, transgenic overexpression of activated PPARd at birth
preprograms the nascent myofibers to transdifferentiate into
slow-twitch fibers, thus imparting a high basal endurance capac-
ity to adult transgenic mice. Apparently, once fiber type specifi-
cation is complete in adults, the potential plasticity of muscle to
synthetic activation of a single transcriptional pathway is con-
strained. Along these lines, the unexpected yet successful
reprogramming of endurance in untrained adults with synthetic
AMP-mimetic might be linked to the ability of AMPK to simulta-
neously target multiple transcriptional programs governed by its
substrates such as PGC1a, PPARa and PPARd, triggering a ge-
netic effect akin to exercise (Hong et al., 2003; Leff, 2003; Bron-
ner et al., 2004; Ja¨ger et al., 2007).
Interestingly, the recalcitrance of adult skeletal muscle endur-
ance tomanipulation by PPARd agonist alone is relieved by com-
bining drug treatment with exercise. Indeed, this strategy gener-
ates an endurance gene signature that is unique from either
paradigm alone, reflecting a crosstalk between exercise and
PPARd signaling (Table S2). Although exercise activates a cas-
cade of signaling events, we feel AMPK is central to this genetic
adaptation for several reasons. First, AMPK is a metabolic sen-
sor that detects low ATP levels (such as occur during exercise)
and in turn increases oxidative metabolism (Mu et al., 2001;
Reznick and Shulman, 2006). Second, long-term effects of
AMPK are in part mediated via regulation of gene expression
(Reznick and Shulman, 2006). Third, exercise induces activation
and nuclear import of AMPK, where it can potentially interact
with transcription factors (this study and McGee et al. [2003]).
And finally, transgenic mice defective for AMPK activation ex-
hibit reduced voluntary exercise (Mu et al., 2001; Thomson
et al., 2007), making it an attractive exercise cue that modulates
receptor signaling.
The notion that exercise-activated AMPK interacts with
PPARd in regulating gene expression is supported by our dem-
onstration that AMPK associates with PPARd and dramatically
increases basal and ligand-dependent transcription via the re-
ceptor. Despite physical interaction, we found that AMPK does
not induce PPARd phosphorylation in metabolic labeling stud-
ies. Interestingly, AMPK and its previously reported substrate
PGC1a synergistically increased PPARd transcription, suggest-
ing indirect regulation of receptor function by AMPK via coregu-
lator modification. Nevertheless, we cannot rule out the possible
regulation of PPARd by AMPK via direct protein-protein interac-
tion. Indeed, regulation of other transcription factors by AMPK
via similar mechanisms has been previously demonstrated
(Hong et al., 2003; Leff, 2003; Bronner et al., 2004). A physiolog-
ical validation of AMPK-PPARd interaction comes from our
observation that GW1516 and AICAR (AMPK activator) synergis-412 Cell 134, 405–415, August 8, 2008 ª2008 Elsevier Inc.tically induce several endurance-related genes in wild-type but
not in PPARd null primary muscle cells. More importantly, treat-
ment of animals with AICAR and GW1516 creates a gene signa-
ture in skeletal muscle that replicates up to 40% of the genetic
effects of combined exercise and GW1516 treatment. Notably,
the shared genes between the two profiles are linked to oxidative
metabolism, angiogenesis, and glucose sparing, pathways that
are directly relevant to muscle performance (Figure 4D, listed
in Table S4).
Although not all genes regulated by either exercise (data not
shown) or exercise-PPARd interaction (nonoverlapping signa-
ture, Figure 4D) are AMPK dependent, two key findings assign
a critical role for the kinase in promoting endurance compared
to other known exercise signals (Bassel-Duby and Olson,
2006; Goodyear et al., 1996; Lagouge et al., 2006). First,
AMPK is constitutively active in VP16-PPARd transgenic mus-
cles that exhibit endurance without exercise. Second, AMPK
activation by AICAR was sufficient to increase running endur-
ance without additional exercise signals. Strikingly, the majority
of the oxidative genes (30 out of 32) upregulated by AICAR are
active in super-endurance VP16-PPARd mice and perhaps are
the core set of genes required to improve muscle performance.
Interestingly, AICAR failed to induce oxidative gene expression
in PPARd null muscle cells, indicting the requirement of PPARd,
at least for regulation of oxidative metabolism by AMPK. Collec-
tively, these findings demonstrate a molecular partnership
between AMPK and PPARd in reprogramming skeletal muscle
transcriptome and endurance (Figure 6I) that can be readily ex-
ploited by orally active AMPK drugs to replace exercise.
In humans, endurance exercise leads to physiological adapta-
tions in the cardiopulmonary, endocrine, and neuromuscular
systems (Jones and Carter, 2000; Lucia et al., 2001). Although
our current investigation focused on skeletal muscle, extramus-
cular effects of PPARd, AMPK, and exercise may also contribute
to increased endurance. Although potentiation of extramuscular
adaptations by PPARd and AMPK agonists remains to be stud-
ied, we found that drug treatment can reduce epididymal fat
mass, possibly conferring additional systemic benefits. It is note-
worthy that PPARd is important for normal cardiac contractility,
as well as for the endocrine function of adipose tissue (Wang
et al., 2003; Cheng et al., 2004). Similarly, the activation of
AMPK by metformin is thought to mediate its ability to lower
blood glucose levels (Shaw et al., 2005). In addition to increasing
performance in athletes, exercise has beneficial effects in a wide
range of pathophysiological conditions, such as respiratory
disorders, cardiovascular abnormalities, type 2 diabetes, and
cancer risk. Therefore, understanding the effects of exercise
on normal physiology and identifying pharmaceutically target-
able pathways that can boost these effects is crucial. In this
study, we revealed that synthetic PPARd activation and exer-
cise—and, more importantly, AMPK activation alone—provide
a robust transcriptional cue that reprograms the skeletal muscle
genome and dramatically enhances endurance. We believe that
the strategy of reorganizing the preset genetic imprint of muscle
(as well as other tissues) with exercise mimetic drugs has thera-
peutic potential in treating certain muscle diseases such as
wasting and frailty as well as obesity where exercise is known
to be beneficial.
EXPERIMENTAL PROCEDURES
Exercise Training and Drug Treatment
Male C57B/6J mice (8 weeks old) were randomly divided into four cohorts
comprising (1) vehicle-treated and sedentary (V), (2) GW1516-treated and sed-
entary (GW), (3) vehicle-treated and exercise-trained (Tr), and (4) GW1516-
treated and exercise-trained (Tr+GW) mice (n = 9). Mice in all groups were
acclimated to moderate treadmill running (10 m/min for 15 min) every other
day for 1 week. After acclimation, basal running endurances for the four groups
were determined via a treadmill running test, where the speed was gradually
increased from 0 to 15 m/min and then maintained constant until exhaustion
(week 0). After the initial test, the mice in the exercise groups were subjected
to 4weeks (5 days/week) of exercise training. Themicewere trained on a tread-
mill inclined at 5, with progressively increasing intensity and time. At the end
of 4 weeks, all exercise-trained mice were running for 50 min/day at 18 m/min.
During the 4 weeks, mice from both the sedentary and trained groups were
treated with either vehicle or GW1516 (5 mg/kg/day). At the end of the drug
treatment and/or training protocol (week 5), six mice per group were subjected
to the running test. Three mice in each group were not subjected to treadmill
test to confirm that changes observed in the skeletal muscle were not due to
the acute run, but related to the exercise training. It should be noted that the
above interventions do not affect body weight and food intake in mice (data
not shown).
In another study, male C57B/6J mice (8 weeks old) were treated with
GW1516 (5 mg/kg/day, oral gavage), AICAR (250 mg/kg/day, i.p.), or the com-
bination of the two drugs for 6 days for gene expression analysis. Additionally,
C57B/6Jmice (8weeks old) were also treatedwith AICAR (500mg/kg/day, i.p.)
for 4 weeks for treadmill running tests.
Tissue Collection
The animals were euthanized by carbon dioxide asphyxiation 72 hr after the
last bout of exercise. Gastrocnemius and quadriceps were isolated, frozen,
and stored at 80C until further analysis. In GW1516/AICAR study, quadri-
ceps were similarly collected on the sixth day 4 hr after drug treatment.
Metachromatic Staining and Histology
Cryosectioning of frozen gastrocnemius and metachromatic ATPase staining
was performed as previously described (Wang et al., 2003, 2004).
Gene and Protein Expression Analysis
RNA was extracted from gastrocnemius or quadriceps with Trizol and
analyzed for gene expression via real-time quantitative PCR. Protein homog-
enates were prepared from quadriceps and analyzed by western blotting
with myoglobin (Dako), UCP3 (Affinity Bioreagents), CYCS (Santacruz),
SCD1 (Santacruz), tubulin (Sigma), phospho-, total-AMPK a, and phospho-
ACC antibodies (Cell Signaling).
Microarray Analysis
Genome-wide analysis was performed in quadriceps from V, GW, Tr, and
Tr+GW mice and from V, GW, AICAR, and AICAR+GW mice, as well as from
wild-type and VP16-PPARd transgenic mice. Preparation of in vitro transcrip-
tion products, oligonucleotide array hybridization, and scanning were per-
formed through the use of Affymetrix high-density oligonucleotide arraymouse
genome 430A 2.0 chips according to Affymetrix protocols. For the minimiza-
tion of discrepancies due to variables, the raw expression data were scaled
with Affymetrix MICROARRAY SUITE 5.0 software, and pairwise comparisons
were performed. The trimmed mean signal of all probe sets was adjusted to
a user-specified target signal value (200) for each array for global scaling.
No specific exclusion criteria were applied. Additional analysis was performed
with the freeware program BULLFROG 7 (Zapala et al., 2002) and the Java-
based statistical tool VAMPIRE (Hsiao et al., 2004).
Cell Culture and Transfection Experiments
Primary muscle cells were isolated fromwild-type and PPARd null mice as pre-
viously described (Rando and Blau, 1994). These cells were treated with drugs
as described in the figure legends. AD 293 cells were cultured in DMEM con-
taining 10% serum and penicillin-streptomycin cocktail. Transfections withCMX-Flag, CMV-myc, pTAP, CMX-Flag PPARd, pTAP-PPARd, CMX-
Tk-PPRE, CMX-bGAL, CMV-myc-hAMPK (a1 and a2 subunits), or CMX-Flag
PGC1awere performedwith Lipofectamine 2000. Skeletal muscle C2C12 cells
were cultured in DMEM containing 20% serum and penicillin-streptomycin
cocktail. For differentiation, cells at 80% confluence were switched to a differ-
entiation medium (DMEM + 2% serum) for 4 days to obtain differentiated my-
otubules. Drug treatments are described in the figure legends.
Immunoprecipitation and Western Blotting
Flag-PPARd or Flag-PGC1a was immunoprecipitated from cell lysates with
anti-Flag conjugated agarose beads (Sigma). For coimmunoprecipitation
experiments, SDS was excluded from the lysis buffer. Western blotting was
performed with rabbit anti-Flag, AMPK a subunit, or PPARd antibodies. For
metabolic labeling, transfected AD 293 cells were treated with p32 for 2 hr be-
fore immunoprecipitation.
Data Analysis
Data was analyzed with either one-way ANOVA with an appropriate post hoc
test for comparison of multiple groups or unpaired student’s t test for compar-
ison between two groups as described in figure legends.
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